Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary ...

Compass Therapeutics recently reported that its Phase 2/3 COMPANION-002 trial in previously treated advanced biliary tract cancer met the primary endpoint, with tovecimig plus paclitaxel achieving ...

In Turkish patients from 44 centers, the R1 resection rate was higher among the EOBTC, which may reflect higher curative intent in younger patients. Recurrence-free survival (RFS) and overall survival ...

Shares of Compass Therapeutics rose after the company said it would host a webcast to review data from its Phase 2/3 study of a potential treatment for advanced biliary tract cancer. The stock gained ...

Zanidatamab, a bispecific HER2-targeted antibody, delivered clinically meaningful and durable responses for patients with HER2-positive biliary tract cancer (BTC), according to final results from the ...

Ateganosine combined with Libtayo shows improved progression-free survival in advanced non-small cell lung cancer, suggesting potential long-term use. Spevatamig, a bispecific antibody, is being ...

Biliary tract cancers, including intrahepatic, perihilar, and extrahepatic cholangiocarcinoma and gallbladder cancer, are among the most aggressive gastrointestinal malignancies. Treatment options ...

Biliary tract cancers, including cholangiocarcinoma and gallbladder carcinoma, represent a heterogeneous group of malignancies with rising global incidence and persistent dismal prognoses. Research in ...

Webcast scheduled for Monday, April 27, 2026 at 8:00am ET. BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical ...

Advanced biliary tract cancer represents one of the most challenging gastrointestinal malignancies in China, with increasing incidence and extremely poor prognosis due to late-stage diagnosis and ...

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secon ...